Low NAD(P)H: Quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children

Blood

Volumn 100, Issue 13, 2002, Pages 4590-4593

  Smith, Martyn T ^a,b   Wang, Yunxia ^a,b   Skibola, Christine F ^a,b   Slater, Diana J ^a,b   Lo Nigro, Luca ^a,b   Nowell, Peter C ^a,b   Lange, Beverly J ^a,b   Felix, Carolyn A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

AGE; ARTICLE; CELL LINEAGE; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME LOCALIZATION; ETHNIC DIFFERENCE; FEMALE; GENE TRANSLOCATION; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; INFANT; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0037114637     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0264     Document Type: Article

References (35)

1. Ernster L. DT-diaphorase: Its structure, function, regulation, and role in antioxidant defence and cancer chemotherapy. In: Yagi K, ed. Pathophysiology of Lipid Peroxides and Related Free Radicals. Basel, Switzerland: S Karger; 1998:149-168.
2. Ross D. Quinone reductases. In: Guengerich FP, ed. Comprehensive Toxicology. Vol 3. New York, NY: Pergamon Press; 1997:179-197.
3. Traver RD, Horikoshi T, Danenberg KD, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Research. 1992;52:797-802.
4. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999;9:113-121.
5. Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 1997;76:852-854.
6. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 1995;5:199-206.
7. Schulz WA, Krummeck A, Rösinger I, Schmitz-DrAger BJ, Sies H. Predisposition towards urolithiasis associated with the NQO1 null-allele. Pharmacogenetics. 1998;8:453-454.
8. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev. 1997;6:87-92.
9. Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor for hematologic malignancy, is associated with NQO1 609 C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997;57:2839-2842.
10. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999;94:803-807.
11. Smith MT, Wang Y, Kane E, et al. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood. 2001;97:1422-1426.
12. Wlemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res. 1999;59:4095-4099.
13. Felix CA, Hosler MR, Slater DJ, et al. MLL genomic breakpoint distribution within the break-point cluster region in de novo leukemia in children. J Pediatr Hematol/Oncol. 1998;20:299-308.
14. Felix CA, Hosler MR, Winick NJ, Masterson M, Wilson AE, Lange BJ. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood. 1995;85:3250-3256.
15. Felix CA, Poplack DG, Reaman GH, et al. Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol. 1990;8:431-442.
16. Nowell P, Finan J. Chromosome studies in preleukemic states. IV. Myeloproliferative versus cytopenic disorders. Cancer. 1978;42:2254-2261.
17. Felix C, Kim C, Megonigal M, et al. Panhandle PCR amplifies genomic translocation breakpoint involving unknown partner gene. Blood. 1997;90:4679-4686.
18. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A. 1998;95:13176-13181.
19. Lo Nigro L, Rappaport E, Slater D, et al. Rapid isolation of genomic translocation breakpoints involving MLL and unknown AF-4 intronic sequences or MLL and unknown partner genes [abstract]. Proc ASCO. 1999;18:565a.
20. Megonigal MD, Rappaport EF, Wilson RB, et al. Panhandle PCR for cDNA: A rapid method for isolation of MLL fusion transcripts involving unknown partner genes. Proc Natl Acad Sci U S A. 2000;97:9597-9602.
21. Raffini LJ, Slater DJ, Rappaport EF, et al. Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MILL translocations and identify complex translocation of MILL, AF-4, and CDK6. Proc Natl Acad Sci U S A. 2002;99:4568-4573.
22. Megonigal MD, Rappaport EF, Jones DH, et al. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc Natl Acad Sci U S A. 1997;94:11583-11588.
23. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997;75:69-75.
24. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: Histology-specific incidence and trends, 1973-1992. J Pediatr Hematol/Oncol. 1997;19:428-432.
25. Heerema NA, Sather HN, Ge J, Hilden JM, Trigg ME, Reaman GH. Cytogenetic studies of infant acute lymphoblastic leukemia: Poor prognosis of infants with t(4;11) - A report of the Children's Cancer Group. Leukemia. 1999;13:679-686.
26. Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila Trithorax, to the AF-4 gene. Cell. 1992;71:701-708.
27. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol. 2001;36:525-535.
28. Ford AM, Ridge SA, Cabrera ME, et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature. 1993;363:358-360
29. Gale K, Ford A, Repp R, et al. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal bloodspots. Proc Natl Acad Sci U S A. 1997;94:13950-13954.
30. Ross JA, Potter JD, Reaman GH, Pendergrass TW, Robison LL. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the Children's Cancer Group. Cancer Causes and Control. 1996;7:581-590.
31. Ross JA. Maternal diet and infant leukemia: A role for DNA topoisomerase II inhibitors? Int J Cancer. 1998;11(suppl):26-28.
32. Corbett A, Osheroff N. When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol. 1993;6:585-597.
33. Valerio LG Jr. Kepa JK, Pickwell GV, Quattrochi LC. Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicology Letters. 2001;119:49-57.
34. McDonald TA, Holland NT, Skibola C, Duramad P, Smith MT. Hypothesis: Phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia. Leukemia. 2001;15:10-20.
35. Chen H, Eastmond DA. Topoisomerase inhibition by phenolic metabolites: A potential mechanism for benzene's clastogenic effects. Carcinogenesis. 1995;16:2301-2307.